SEPN

Septerna Inc

41.86

Nov 12 • 3:59 PM ET -6.70 (-13.80%)

41.10

Aftermarket • 7:30 PM ET -0.76 (-1.82%)

Healthcare Biotechnology USA Small NASD

Today, 8:32 PMNo clear catalyst identified; Septerna 14% drop exceeds XBI on no fresh news

Peers: GPCR MBX ASND MLYS RYTM PTGX RARE TECX RZLT ANRO

| Held by: VTI IWM XPH IBB FYC VXF IWO SCHA FYX VTWO

Scroll to Statements

Index	RUT
Market Cap	1.99B
Enterprise Value	1.53B
Income	-59.00M
Sales	96.27M
Book/sh	9.03
Cash/sh	10.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	130
IPO	Oct 25, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	20.68
P/B	4.64
P/C	4.16
P/FCF	-
EV/EBITDA	-
EV/Sales	15.93
Quick Ratio	4.84
Current Ratio	4.84
Debt/Eq	0.05
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-1.29
EPS next Y	-2.31
EPS next Q	-0.44
EPS this Y	-30.36%
EPS next Y	-61.02%
EPS next 5Y	-
EPS past 3/5Y	-18.79% -
Sales past 3/5Y	- -
EPS Y/Y TTM	14.29%
Sales Y/Y TTM	336.69%
EPS Q/Q	-416.29%
Sales Q/Q	-12.16%
Earnings	Nov 09 AMC
EPS/Sales Surpr.	-37.35% -9.14%

Insider Own	36.22%
Insider Trans	-8.39%
Inst Own	66.40%
Inst Trans	3.68%
ROA	-9.62%
ROE	-14.45%
ROIC	-13.19%
Gross Margin	98.29%
Oper. Margin	-76.23%
Profit Margin	-61.29%
SMA20	-4.60%
SMA50	3.75%
SMA200	26.73%
Trades

Shs Outstand	47.41M
Shs Float	30.33M
Short Float	11.05%
Short Ratio	8.16
Short Interest	3.35M
52W High	53.34 -21.52%
52W Low	18.64 124.57%
Volatility	11.67% 7.69%
ATR (14)	3.48
RSI (14)	46.30
Beta	2.18
Rel Volume	1.48
Avg Volume	411.08K
Volume	608,599

Perf Week	-11.59%
Perf Month	15.25%
Perf Quarter	-5.93%
Perf Half Y	47.81%
Perf YTD	50.14%
Perf Year	117.68%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	59.22
Prev Close	48.56
Price	41.86
Change %	-13.80%

Consensus

Strong Buy

Avg. Price Target

$59.22

Implied Upside

+41.5%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 11, 2026	Initiated	GGuggenheim	Buy	$52	+24.2%
May 01, 2026	Initiated	SStifel	Buy	$43	+2.7%
Dec 19, 2025	Initiated	RRaymond James	Strong Buy	$38	-9.2%
Dec 15, 2025	Initiated	TTruist	Buy	$34	-18.8%
Nov 14, 2025	Upgrade	WWells Fargo	Equal Weight → Overweight
Jun 23, 2025	Initiated	HH.C. Wainwright	Buy	$26	-37.9%
Feb 18, 2025	Downgrade	WWells Fargo	Overweight → Equal Weight	$14	-66.6%
Nov 19, 2024	Initiated	WWells Fargo	Overweight	$43	+2.7%
Nov 19, 2024	Initiated	TTD Cowen	Buy
Nov 19, 2024	Initiated	JJP Morgan	Overweight	$38	-9.2%
Nov 19, 2024	Initiated	CCantor Fitzgerald	Overweight	$50	+19.4%

Nov-09-26 04:01PM	Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-04-26 08:00AM	Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting (GlobeNewswire) +9.57%
Nov-03-26 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-10-26 04:00PM	Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Aug-25-26 08:00AM	Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer (GlobeNewswire)
Aug-10-26 04:01PM	Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results (GlobeNewswire) +22.93%
Jun-08-26 08:00AM	Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting (Business Wire)
May-11-26 04:01PM	Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire) +5.39%
May-05-26 08:00AM	Septerna to Present at Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-13-26 08:00AM	Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism (GlobeNewswire)
Mar-09-26 05:20PM	Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-01-26 09:45AM	Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy (GlobeNewswire)
Feb-24-26 08:00AM	Septerna to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +10.21%
04:05PM	Loading…
Feb-10-26 04:05PM	Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting (GlobeNewswire)
Jan-08-26 04:05PM	Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-17-25 08:00AM	Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-25 08:00AM	Septerna to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-06-25 09:15AM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 04:56AM	Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? (Zacks)
Oct-22-25 05:57AM	Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Oct-15-25 04:15PM	Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead (MarketBeat)
Oct-09-25 10:13AM	Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? (Zacks)
Oct-03-25 08:42AM	Are Options Traders Betting on a Big Move in Septerna Stock? (Zacks)
04:01PM	Loading…
Sep-29-25 04:01PM	Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors (GlobeNewswire)
Aug-27-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases (GlobeNewswire) +5.50%
Aug-14-25 08:15AM	Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (Reuters)
Aug-11-25 04:01PM	Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
May-29-25 08:00AM	Septerna to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:55AM	Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? (Zacks)
May-15-25 04:01PM	Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
08:46AM	Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk (Zacks)
07:45AM	Is It Time to Buy the Dip in Novo Nordisk Stock? (MarketBeat)
01:45AM	Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills (The Wall Street Journal)
May-14-25 04:06PM	Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing (Investor's Business Daily) +50.97%
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
01:29PM	Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies (Pharmaceutical Technology)
10:28AM	Novo Nordisk Rises on Weight-Loss News. Its a Huge Deal for This Stock. (Barrons.com)
09:35AM	Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill (Yahoo Finance Video)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
07:03AM	Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments (Reuters)
Apr-16-25 09:55AM	Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know (Zacks)
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha) -5.08%
Mar-27-25 08:00AM	Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-14-25 11:26AM	Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-05-25 06:59PM	Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +7.25%
Feb-26-25 08:00AM	Septerna to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist (GlobeNewswire) -46.99%
Feb-14-25 06:45AM	Its not for the faint of heart. How 3 CEOs took their biotechs public (BioPharma Dive) +12.21%
Feb-06-25 07:48AM	Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey)
Jan-06-25 07:00AM	Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer (GlobeNewswire) -6.75%
Dec-18-24 08:00AM	Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 11:12PM	Septerna, Inc. Reports Q3 2024 Financials and Progress (TipRanks)
Nov-20-24 07:00AM	Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
05:10AM	Septerna initiated with an Overweight at JPMorgan (TipRanks)
Oct-30-24 04:41PM	Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering (GlobeNewswire) +12.32%
Oct-24-24 09:47PM	Septerna Prices Upsized Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samsara BioCapital, L.P.	Shareholder	Nov 12 '26	Proposed Sale	48.56	306,645	14,890,681		Nov 12 05:59 PM
JEFFREY FINER	Director	Nov 12 '26	Proposed Sale	48.56	66,000	3,204,960		Nov 12 04:21 PM
ALAN EZEKOWITZ	Director	Nov 11 '26	Proposed Sale	52.34	100,000	5,234,000		Nov 12 07:56 AM
Bhatt Elizabeth	President and COO	Oct 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Oct 19 07:00 PM
Bhatt Elizabeth	President and COO	Oct 15 '26	Sale	37.41	4,000	149,644	174,209	Oct 19 07:00 PM
DANIEL LONG	Officer	Oct 01 '26	Proposed Sale	39.13	10,001	391,339		Oct 01 04:32 PM
SAMIRA SHAIKHLY	Officer	Oct 01 '26	Proposed Sale	39.13	12,592	492,725		Oct 01 04:24 PM
Long Daniel D.	SVP, Drug Discovery	Sep 01 '26	Option Exercise	2.76	3,333	9,199	99,745	Sep 03 07:01 PM
Long Daniel D.	SVP, Drug Discovery	Sep 01 '26	Sale	37.83	3,333	126,078	96,412	Sep 03 07:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Aug 12 '26	Sale	42.50	1,493,000	63,452,500	725,443	Aug 14 05:11 PM
Bhatt Elizabeth	President and COO	Aug 11 '26	Option Exercise	5.79	25,000	144,658	199,209	Aug 13 07:00 PM
Bhatt Elizabeth	President and COO	Aug 11 '26	Sale	44.00	25,000	1,100,000	174,209	Aug 13 07:00 PM
RA Capital Healthcare Fund LP	affiliate	Aug 12 '26	Proposed Sale	48.19	746,500	35,973,835		Aug 12 07:06 PM
RA Capital Nexus Fund III, L.P	Affiliate	Aug 12 '26	Proposed Sale	48.19	746,500	35,973,835		Aug 12 06:55 PM
Third Rock Ventures V, L.P.	10% Owner	Aug 12 '26	Proposed Sale	51.00	147,200	7,507,200		Aug 12 04:09 PM
ELIZABETH P. BHATT	Officer	Aug 11 '26	Proposed Sale	38.85	29,000	1,126,650		Aug 11 04:28 PM
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Option Exercise	2.76	3,334	9,202	99,746	Aug 05 07:00 PM
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Sale	34.47	3,334	114,920	96,412	Aug 05 07:00 PM
Bhatt Elizabeth	President and COO	Jul 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Jul 17 07:00 PM
Bhatt Elizabeth	President and COO	Jul 15 '26	Sale	33.99	4,000	135,974	174,209	Jul 17 07:00 PM
ELIZABETH P. BHATT	Officer	Jul 15 '26	Proposed Sale	34.54	4,000	138,160		Jul 15 04:23 PM
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Option Exercise	2.76	3,333	9,199	99,745	Jul 02 07:00 PM
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Sale	34.36	3,333	114,528	96,412	Jul 02 07:00 PM
Shaikhly Samira	Chief People Officer	Jun 29 '26	Option Exercise	6.81	2,178	14,832	2,971	Jun 30 07:01 PM
Shaikhly Samira	Chief People Officer	Jun 29 '26	Sale	35.18	2,178	76,622	793	Jun 30 07:01 PM
JAE KIM	Officer	Jun 26 '26	Proposed Sale	36.61	2,438	89,243		Jun 26 04:02 PM
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Option Exercise	5.42	15,000	81,371	111,412	Jun 24 07:24 PM
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Sale	35.51	15,000	532,582	96,412	Jun 24 07:24 PM
DANIEL LONG	Officer	Jun 22 '26	Proposed Sale	36.17	25,000	904,250		Jun 22 04:40 PM
JAE KIM	Officer	Jun 22 '26	Proposed Sale	35.26	94,339	3,326,120		Jun 22 04:16 PM
Shaikhly Samira	Chief People Officer	Jun 12 '26	Option Exercise	11.70	6,250	73,125	7,043	Jun 16 08:31 PM
Shaikhly Samira	Chief People Officer	Jun 12 '26	Sale	35.08	6,250	219,224	793	Jun 16 08:31 PM
SAMIRA SHAIKHLY	Officer	Jun 12 '26	Proposed Sale	34.03	8,428	286,805		Jun 12 04:42 PM
Shaikhly Samira	Chief People Officer	Jun 01 '26	Option Exercise	1.87	5,935	11,111	6,728	Jun 03 07:11 PM
Shaikhly Samira	Chief People Officer	Jun 01 '26	Sale	28.93	5,935	171,682	793	Jun 03 07:11 PM
Shaikhly Samira	Chief People Officer	May 26 '26	Option Exercise	6.81	11,798	80,344	12,591	May 28 07:02 PM
Shaikhly Samira	Chief People Officer	May 26 '26	Sale	30.06	11,798	354,656	793	May 28 07:02 PM
SAMIRA SHAIKHLY	Officer	May 26 '26	Proposed Sale	28.36	11,798	334,591		May 26 04:41 PM
Bhatt Elizabeth	President and COO	Apr 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Apr 17 07:00 PM
Bhatt Elizabeth	President and COO	Apr 15 '26	Sale	24.34	4,000	97,343	174,209	Apr 17 07:00 PM
Shaikhly Samira	Chief People Officer	Mar 02 '26	Option Exercise	1.84	70,453	129,456	71,246	Mar 04 07:00 PM
Shaikhly Samira	Chief People Officer	Mar 02 '26	Sale	28.10	70,453	1,979,838	793	Mar 04 07:00 PM
SAMIRA SHAIKHLY	Officer	Mar 02 '26	Proposed Sale	29.02	76,388	2,216,780		Mar 02 04:36 PM
Bhatt Elizabeth	President and COO	Feb 18 '26	Option Exercise	6.81	4,000	27,240	178,209	Feb 20 05:28 PM
Bhatt Elizabeth	President and COO	Feb 18 '26	Sale	28.97	4,000	115,860	174,209	Feb 20 05:28 PM
ELIZABETH BHATT	Officer	Feb 18 '26	Proposed Sale	30.30	8,000	242,400		Feb 18 04:27 PM

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Ph.D.Dr. Jeffrey T. Finer M.D.

M.S.Ms. Elizabeth P. Bhatt M.B.A.

J.D.Mr. Gilbert M. Labrucherie C.F.A.

Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory BoardDr. Robert J. Lefkowitz M.D.

Ph.D.Dr. Arthur Christopoulos BPHARM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

SEPN

Septerna Inc

Upgrade your Finviz experience

All the Features.
Half the Price.